AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action

Naloxegol is currently a Schedule II controlled substance due to its structural similarity to another compound; AstraZeneca seeks descheduling of the constipation drug, which labeling states poses no risk of abuse or dependency.